Defense Stock Face-Off: Northrop Grumman vs. Lockheed Martin -- Which Is the Better Buy Right Now?

Northrop Grumman posted Q1 revenue of $9.8 billion, up 4% year over year, and EPS of $6.14, up 85%, while Lockheed Martin reported Q1 sales of $18 billion, up less than 1%, and EPS of $6.44, down 12%. Northrop’s $95.6 billion backlog and Lockheed’s $186.4 billion backlog support long-term visibility, while both continue to return capital through dividends and buybacks. The article favors Lockheed for income and scale, but frames Northrop as the better value choice due to its lower 17x P/E versus Lockheed’s 25x.

Analysis

The market is conflating “headline defense demand” with “equity quality.” The cleaner read is that NOC has the more powerful near-to-mid-term operating inflection because it is finally stepping out of the most margin-destructive phase of its largest development program, which should create a step-change in cash conversion before revenue growth fully re-accelerates. That makes the current multiple discount less about secular weakness and more about investors over-penalizing a temporary profitability trough.

LMT’s bigger backlog is real, but a large backlog in this part of the industry is not automatically a better equity signal if too much of it is tied to low-duration, execution-sensitive missile and aircraft production. The second-order issue is that a backlog-heavy profile can actually mask margin compression if the mix shifts toward faster-delivery hardware before sustainment dollars ramp. The market likely underestimates how quickly F-35 and missile-defense sustainment can turn LMT into a higher-quality annuity, but that monetization is a multi-year rather than a next-quarter story.

The key contrarian setup is that the selloff has probably overshot the fundamental delta between the two names. NOC screens as the better value/FCF acceleration story over the next 6-18 months, while LMT is the better “sleep well” compounder over 3+ years because the backlog and service mix reduce earnings volatility. The main risk to both is not demand, but fixed-price execution and political pressure around cost overruns; a single adverse program review could delay multiple expansion even if end-demand stays intact.

Relative value is where this becomes interesting: the cleanest expression is long NOC / short LMT for investors expecting mean reversion in valuation gaps as NOC’s production economics improve faster than consensus expects. If you want lower beta, own LMT on pullbacks and finance it with an out-of-the-money covered call to monetize the rich multiple while waiting for sustainment earnings to show up. For a tactical trade, look for post-earnings weakness in either name to add, because the sector’s medium-term rerating will likely come from margin inflection, not order growth.

Key Decisions for Investors

• Long NOC / short LMT as a 3-6 month relative value trade: thesis is NOC’s margin inflection will be recognized sooner, while LMT’s backlog quality premium is already partly priced in.
• Add to NOC on any pullback toward value-support levels over the next 1-2 months; target a 12-18 month hold for cash-flow normalization and multiple re-rating, with downside limited by buyback/dividend support.
• Own LMT as a core defensive compounder for 12+ months, but consider covered calls against the position to monetize elevated valuation while waiting for sustainment growth to inflect.
• Avoid chasing either name after positive headline prints; initiate only on weakness because both remain vulnerable to fixed-price program noise, which can trigger 5-10% drawdowns on execution headlines.
• If you want lower-risk exposure to the theme, pair long NOC with a smaller short in a defense industrial basket or broader industrials ETF to isolate the operating-margin reversion trade rather than the sector beta.